ClinicalTrials.gg
CompletedNCT02662569BERSONUpdated Jan 11, 2019Results posted

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

A Phase 3 interventional study of Evolocumab and Atorvastatin in Diabetes, Hyperlipidemia, Mixed Dyslipidemia, sponsored by Amgen. Completed at 110 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-11.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
986
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.

Enrollment
29th of 280
986 · median 143
Started
2016
with 18 others
Phase 3
36 of 417
5 open now
Registered
142nd of 417
by date

Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 29th largest by enrollment of the 280 interventional ones that give a count, is one of 19 that started in 2016, is one of 36 in phase 3, and was the 142nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Diabetes Mellitus with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.

03

Conditions studied

  • Diabetes, Hyperlipidemia, Mixed Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females with type 2 diabetes (receiving pharmacologic treatment for at least 6 months or longer) with stable diabetes therapy
  • Lipid-lowering therapy must be unchanged for at least 4 weeks or more
  • Subjects receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 100 mg/dL
  • Subjects not receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 130 mg/dL

Exclusion criteria

Exclusion criteria:

  • (NYHA) class III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes or poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
986 participants (actual)

Study arms

  • Active comparator
    Atorvastatin (Q2W)

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.

    Drug: Atorvastatin · Other: Placebo

  • Active comparator
    Atorvastatin (QM)

    Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.

    Drug: Atorvastatin · Other: Placebo

  • Experimental
    Evolocumab Q2W + Atorvastatin

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.

    Biological: Evolocumab · Drug: Atorvastatin

  • Experimental
    Evolocumab QM + Atorvastatin

    Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.

    Biological: Evolocumab · Drug: Atorvastatin

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • Administered orally once a day

    Also known as: Lipitor

  • OtherPlacebo

    Placebo to evolocumab administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  2. Percent Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  2. Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and week 12

  3. Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  4. Percent Change From Baseline in Non-HDL-C at Week 12

    Time frame: Baseline and week 12

  5. Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  6. Percent Change From Baseline in Apolipoprotein B100 at Week 12

    Time frame: Baseline and week 12

  7. Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  8. Percent Change From Baseline in Total Cholesterol at Week 12

    Time frame: Baseline and week 12

  9. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  10. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

    Time frame: Baseline and week 12

  11. Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  12. Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12

    Time frame: Baseline and week 12

  13. Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)

    Time frame: Weeks 10 and 12

  14. Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12

    Time frame: Week 12

  15. Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  16. Percent Change From Baseline in Lipoprotein(a) at Week 12

    Time frame: Baseline and week 12

  17. Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  18. Percent Change From Baseline in Triglycerides at Week 12

    Time frame: Baseline and week 12

  19. Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

  20. Percent Change From Baseline in HDL-C at Week 12

    Time frame: Baseline and week 12

  21. Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and weeks 10 and 12

07

Results

Posted Jan 11, 2019

Participant flow

Participants were enrolled at 102 study centers and randomized at 98 centers in Argentina, Brazil, Canada, China, Colombia, France, Republic of Korea, Russian Federation, Turkey, and the United States from 14 April 2016 to 28 July 2017.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Started166161327332
Received study drug164160325332
Completed159160321328
Not completed7164
Withdrew: Withdrawal by subject6164
Withdrew: Lost to follow-up1000

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 124.94 ± 3.480.99 ± 3.31-65.35 ± 3.09-69.05 ± 2.96
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -70.29 · 95% CI -75.43 to -65.16Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -70.04 · 95% CI -74.67 to -65.41Treatment difference = Evolocumab QM - Placebo QM
PrimaryPercent Change From Baseline in LDL-C at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at Week 127.10 ± 3.662.63 ± 3.41-64.66 ± 3.20-62.30 ± 3.02
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -71.77 · 95% CI -77.61 to -65.93Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -64.93 · 95% CI -69.97 to -59.89Treatment difference = Evolocumab QM - Placebo QM
SecondaryChange From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
mg/dLPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-2.1 ± 4.1-8.8 ± 4.0-64.6 ± 3.6-71.9 ± 3.6
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -62.5 · 95% CI -68.2 to -56.9Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -63.1 · 95% CI -68.4 to -57.8Treatment difference = Evolocumab QM - Placebo QM
SecondaryChange From Baseline in LDL-C at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at Week 12-0.3 ± 4.2-7.3 ± 4.1-63.9 ± 3.7-66.1 ± 3.7
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -63.6 · 95% CI -69.7 to -57.6Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -58.8 · 95% CI -64.3 to -53.3Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 124.33 ± 3.050.33 ± 2.95-56.57 ± 2.70-59.08 ± 2.63
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -60.90 · 95% CI -65.51 to -56.29Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -59.40 · 95% CI -63.52 to -55.29Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-HDL-C at Week 125.87 ± 3.201.30 ± 3.03-55.76 ± 2.79-52.92 ± 2.69
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -61.64 · 95% CI -66.82 to -56.45Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.22 · 95% CI -58.70 to -49.74Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 121.97 ± 3.31-1.52 ± 2.99-54.96 ± 3.07-56.37 ± 2.72
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -56.93 · 95% CI -60.93 to -52.93Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.85 · 95% CI -58.52 to -51.18Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Apolipoprotein B100 at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B100 at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B100 at Week 123.17 ± 3.42-0.26 ± 3.03-53.90 ± 3.14-49.68 ± 2.75
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -57.06 · 95% CI -61.59 to -52.54Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.42 · 95% CI -53.31 to -45.53Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 122.89 ± 2.30-0.25 ± 2.18-38.64 ± 2.04-39.74 ± 1.95
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -41.53 · 95% CI -44.95 to -38.10Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -39.50 · 95% CI -42.47 to -36.53Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Total Cholesterol at Week 124.40 ± 2.400.67 ± 2.24-37.82 ± 2.10-35.22 ± 1.99
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -42.22 · 95% CI -46.02 to -38.42Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -35.89 · 95% CI -39.12 to -32.67Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 123.03 ± 2.38-2.03 ± 2.41-41.06 ± 2.11-45.70 ± 2.17
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -44.09 · 95% CI -47.64 to -40.54Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -43.67 · 95% CI -46.90 to -40.44Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 123.22 ± 2.49-1.22 ± 2.47-40.72 ± 2.18-41.78 ± 2.21
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -43.94 · 95% CI -47.90 to -39.97Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -40.56 · 95% CI -44.08 to -37.04Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 122.60 ± 3.30-1.02 ± 3.09-55.60 ± 3.07-57.75 ± 2.82
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -58.20 · 95% CI -62.15 to -54.25Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -56.73 · 95% CI -60.53 to -52.93Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 123.23 ± 3.39-0.10 ± 3.16-54.98 ± 3.12-51.80 ± 2.86
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -58.21 · 95% CI -62.59 to -53.84Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -51.70 · 95% CI -55.81 to -47.59Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame:
Weeks 10 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
percentage of participantsPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)21.7 (15.9 to 28.7)19.4 (13.9 to 26.3)90.1 (86.2 to 92.9)91.3 (87.6 to 93.9)
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 68.4 · 95% CI 60.4 to 74.8Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 71.9 · 95% CI 64.1 to 77.9Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12
percentage of participantsPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 1220.9 (15.2 to 28.2)21.3 (15.5 to 28.6)88.2 (84.0 to 91.4)90.2 (86.2 to 93.1)
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 67.2 · 95% CI 58.9 to 73.9Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 68.8 · 95% CI 60.6 to 75.3Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 1216.89 ± 17.498.48 ± 9.49-38.63 ± 13.67-42.29 ± 8.49
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -55.52 · 95% CI -92.64 to -18.40Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -50.77 · 95% CI -63.82 to -37.72Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein(a) at Week 1226.53 ± 21.787.47 ± 10.40-35.93 ± 16.47-37.85 ± 9.02
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -62.46 · 95% CI -110.89 to -14.03Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -45.32 · 95% CI -61.87 to -28.77Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 1211.54 ± 5.278.48 ± 4.48-6.48 ± 4.70-7.15 ± 4.02
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.0002 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -18.02 · 95% CI -25.89 to -10.14Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -15.63 · 95% CI -21.69 to -9.58Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Triglycerides at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at Week 1210.50 ± 5.368.07 ± 4.57-5.91 ± 4.75-4.24 ± 4.09
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.0002 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -16.41 · 95% CI -24.63 to -8.19Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -12.31 · 95% CI -18.76 to -5.86Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 121.25 ± 2.195.88 ± 2.117.59 ± 1.9913.75 ± 1.90
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.0003 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 6.34 · 95% CI 3.36 to 9.33Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 7.87 · 95% CI 5.10 to 10.65Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in HDL-C at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in HDL-C at Week 122.57 ± 2.296.04 ± 2.188.45 ± 2.0414.18 ± 1.95
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.0003 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 5.88 · 95% CI 2.49 to 9.27Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 8.14 · 95% CI 5.03 to 11.25Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 129.63 ± 4.707.92 ± 4.43-17.55 ± 4.19-16.09 ± 3.99
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -27.18 · 95% CI -34.20 to -20.17Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -24.01 · 95% CI -29.88 to -18.14Treatment difference = Evolocumab QM - Placebo QM

Adverse events

Collected over From the first dose of study drug to 30 days after last dose; up to 14 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/164 (0%)6/164 (3.7%)28/164 (17.1%)
Placebo QM0/160 (0%)5/160 (3.1%)22/160 (13.8%)
Evolocumab Q2W0/325 (0%)10/325 (3.1%)45/325 (13.8%)
Evolocumab QM0/332 (0%)22/332 (6.6%)49/332 (14.8%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Atrial fibrillationCardiac disorders2/1640/1600/3252/332
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1640/1600/3253/332
CataractEye disorders0/1641/1600/3251/332
Lung infectionInfections and infestations0/1641/1600/3250/332
Diabetic ketoacidosisMetabolism and nutrition disorders0/1641/1600/3250/332
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1641/1600/3250/332
Carotid artery stenosisNervous system disorders0/1641/1600/3250/332
Ischaemic strokeNervous system disorders0/1641/1600/3250/332
Cerebral infarctionNervous system disorders0/1640/1602/3250/332
Herpes zoster cutaneous disseminatedInfections and infestations1/1640/1600/3250/332
Most frequent other events
Most frequent other events
EventPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Diabetes mellitusMetabolism and nutrition disorders2/1644/16015/32515/332
Upper respiratory tract infectionInfections and infestations6/1645/1609/32513/332
NasopharyngitisInfections and infestations6/1646/1609/32511/332
HypertensionVascular disorders6/1643/1608/3255/332
HypoglycaemiaMetabolism and nutrition disorders5/1640/1602/3252/332
ArthralgiaMusculoskeletal and connective tissue disorders1/1644/1603/3253/332
CoughRespiratory, thoracic and mediastinal disorders4/1642/1601/3256/332

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Mean61.6 ± 8.861.0 ± 8.861.0 ± 8.561.6 ± 8.461.3 ± 8.6
Age, Customized
Age, Customized(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
18 - 64 years105101206208620
65 - 80 years6160121124366
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Female10294178190564
Male6467149142422
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Hispanic or Latino29346567195
Not Hispanic or Latino137127262265791
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
American Indian or Alaska Native01102
Asian8280164166492
Black or African American76111842
Native Hawaiian or Other Pacific Islander00000
White7268140140420
Multiple5611830
Stratification Factor: Statin Therapy at Study Entry
Stratification Factor: Statin Therapy at Study Entry(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Intensive statin usage1615313294
Non-intensive statin usage8380167166496
No statin6766129134396
Stratification Factor: Geographic Region
Stratification Factor: Geographic Region(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
China7675150152453
South Korea65141338
Other countries8481163167495
Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Mean92.2 ± 32.091.0 ± 30.792.4 ± 33.893.5 ± 33.692.5 ± 32.9

9 further baseline measures are reported on the registry.

08

Study locations

110 sites
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Overland Park, Kansas 66210, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Columbus, Ohio 43212, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Caba, Buenos Aires C1405BUB, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1012AAR, Argentina
  • Research Site
    Mar del Plata, Buenos Aires B7600FZN, Argentina
  • Research Site
    Buenos Aires, C1425ACG, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Brasília, Distrito Federal 71625-009, Brazil
  • Research Site
    Goiania, Goiás 74223-130, Brazil
  • Research Site
    Sao Paulo, São Paulo 01244-030, Brazil
  • Research Site
    Rio De Janeiro, 22271-100, Brazil
  • Research Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Research Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    Woodstock, Ontario N4S 5P5, Canada
  • Research Site
    Laval, Quebec H7T 2P5, Canada
  • Research Site
    Montreal, Quebec H2W 1R7, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    St Jean sur Richelieu, Quebec J3A 1C3, Canada
  • Research Site
    Beijing, Beijing 100853, China
  • Research Site
    Chongqing, Chongqing 404000, China
  • Research Site
    Guangzhou, Guangdong 510080, China
  • Research Site
    Guangzhou, Guangdong 510515, China
  • Research Site
    Nanning, Guangxi 530021, China
  • Research Site
    Guiyang, Guizhou 550002, China
  • Research Site
    Shijiazhuang, Hebei 050051, China
  • Research Site
    Wuhan, Hubei 430014, China
  • Research Site
    Wuhan, Hubei 430030, China
  • Research Site
    Changsha, Hunan 410004, China
  • Research Site
    Changsha, Hunan 410008, China
  • Research Site
    Changsha, Hunan 410013, China
  • Research Site
    Hengyang, Hunan 421001, China
  • Research Site
    Zhuzhou, Hunan 412000, China
  • Research Site
    Baotou, Inner Mongolia 014010, China
  • Research Site
    Nanjing, Jiangsu 210008, China
  • Research Site
    Nanjing, Jiangsu 210011, China
  • Research Site
    Nanjing, Jiangsu 210012, China
  • Research Site
    Nanjing, Jiangsu 210029, China
  • Research Site
    Suzhou, Jiangsu 215021, China
  • Research Site
    Wuxi, Jiangsu 214023, China
  • Research Site
    Xuzhou, Jiangsu 221006, China
  • Research Site
    Zhenjiang, Jiangsu 212001, China
  • Research Site
    Nanchang, Jiangxi 330006, China
  • Research Site
    Changchun, Jilin 130021, China
  • Research Site
    Changchun, Jilin 130033, China
  • Research Site
    ChangChun, Jilin 130041, China
  • Research Site
    Siping, Jilin 136000, China
  • Research Site
    Shenyang, Liaoning 110004, China
  • Research Site
    XI An, Shaanxi 710061, China
  • Research Site
    Jinan, Shandong 250013, China
  • Research Site
    Shanghai, Shanghai 200032, China
  • Research Site
    Chengdu, Sichuan 610041, China
  • Research Site
    Tianjin, Tianjin 300052, China
  • Research Site
    Urumqi, Xinjiang 830054, China
  • Research Site
    Hangzhou, Zhejiang 310003, China
  • Research Site
    Hangzhou, Zhejiang 310013, China
  • Research Site
    Hangzhou, Zhejiang 310014, China
  • Research Site
    Linhai, Zhejiang 318000, China
  • Research Site
    Wenzhou, Zhejiang 325000, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100037, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Shanghai, 200003, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200120, China
  • Research Site
    Medellin, Antioquia 050012, Colombia
  • Research Site
    Barranquilla, Atlántico 08001000, Colombia
  • Research Site
    Barranquilla, Atlántico 080020, Colombia
  • Research Site
    Barranquilla, Atlántico, Colombia
  • Research Site
    Pasto, Nariño, Colombia
  • Research Site
    Dijon, 21079, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Bucheon-si, Wonmi-gu, 420-717, Korea, Republic of
  • Research Site
    Busan, 602-715, Korea, Republic of
  • Research Site
    Busan, 602-739, Korea, Republic of
  • Research Site
    Daegu, 705-718, Korea, Republic of
  • Research Site
    Seongnam-si, 463-707, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 07061, Korea, Republic of
  • Research Site
    Seoul, 110-744, Korea, Republic of
  • Research Site
    Seoul, 110-746, Korea, Republic of
  • Research Site
    Seoul, 130-872, Korea, Republic of
  • Research Site
    Seoul, 137-701, Korea, Republic of
  • Research Site
    Seoul, 139-711, Korea, Republic of
  • Research Site
    Seoul, 152-703, Korea, Republic of
  • Research Site
    Kemerovo, 650002, Russian Federation
  • Research Site
    Moscow, 117292, Russian Federation
  • Research Site
    Moscow, 121552, Russian Federation
  • Research Site
    Saint-Petersburg, 192289, Russian Federation

Showing the first 100 of 110 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Blom DJ, Chen J, Yuan Z, Borges JLC, Monsalvo ML, Wang N, Hamer AW, Ge J. Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes. Endocrinol Diabetes Metab. 2020 Mar 6;3(2):e00123. doi: 10.1002/edm2.123. eCollection 2020 Apr. PubMed 32318641 ↗
  • Chen Y, Yuan Z, Lu J, Eliaschewitz FG, Lorenzatti AJ, Monsalvo ML, Wang N, Hamer AW, Ge J. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab. 2019 Jun;21(6):1464-1473. doi: 10.1111/dom.13700. Epub 2019 Apr 14. PubMed 30851062 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2017, 19 months.

Results were first posted in Jan 2019, 1 year 1 month after primary completion.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 19 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Jan 25, 2016
StartActual
Apr 14, 2016
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Results first posted
Jan 11, 2019
Last update
Jan 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02662569
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 25, 2016
Start date
Apr 14, 2016
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Results posted
Jan 11, 2019
Last update
Jan 11, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion